Analytical instruments, not models, may be China's toughest biotech chokepoint
PAstynome · x · 2026-11-20
PAstynome argues China's real chokepoint is analytical instruments — a market dominated by Agilent, BD, and Thermo-Fisher with Shimadzu as the only major non-US supplier, a dependency as tough as semiconductor fab tools. The quoted post counters that China's biotech ecosystem has no glaring holes: favorable regulation, automated labs at parity, and speed advantages in clinical trials and approvals that outweigh any in silico gains — and it's not about labor costs. A useful snapshot of the instruments-vs-trials debate in US–China biotech competition.
More from Infra
- Touchmark raises $3M seed to build a commodities-style exchange for AI inference contracts — ycombinator · 2026-11-20
- 753B-parameter GLM-5.3 served fully in GPU memory across two NVIDIA DGX Stations — kuchaev · 2026-11-20
- PolyAI's real-time dialog model Dialog-RSN-1 lands on SageMaker JumpStart — AWS ML Blog · 2026-11-20
- Three decommissioned V100s in a $1,042 rig beat a $5,399 Mac Studio at long contexts — bittingthembits · 2026-11-20
- NVIDIA's Rubin debuts in MLPerf Training and Inference as benchmark maintainer congratulates strong quarter — TheKanter · 2026-11-20
- Halocline: hand-rolled CUDA engine runs Qwen4 on one RTX 4090, up to 2.6x faster than Strata — Distinct-Pie2389 · 2026-11-20